Stay updated on Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The page now displays the completed MIRASOL Phase 3 trial record, including its study design, eligibility criteria, outcomes, locations, publications, and documents, instead of a 403 response.
    Difference
    100%
    Check dated 2026-11-11T17:29:03.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    Change Detected
    Summary
    The site footer revision changes from v3.7.2 to v3.8.0 while the page remains a 403 error.
    Difference
    0.2%
    Check dated 2026-10-28T15:44:49.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The clinical-trial record is replaced by a 403 Forbidden message, and an NIH notice about a terminology transition appears at the top of the page.
    Difference
    18%
    Check dated 2026-10-21T20:57:08.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The MIRASOL clinical trial record is now displayed, including study design and results, participant eligibility, locations, and study documents.
    Difference
    100%
    Check dated 2026-10-14T20:57:40.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The site footer’s revision number changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-07T21:45:01.000Z thumbnail image
  7. Check
    52 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error with a minimal header and a Home link. This indicates the study record content is currently unavailable due to access restrictions.
    Difference
    18%
    Check dated 2026-09-23T21:53:38.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.